-+ 0.00%
-+ 0.00%
-+ 0.00%

Jaguar Health says crofelemer trial meets primary endpoint in dogs with chemotherapy-induced diarrhea

PUBT·04/29/2026 12:32:41
Listen to the news
Jaguar Health says crofelemer trial meets primary endpoint in dogs with chemotherapy-induced diarrhea
  • Jaguar Health released topline results from completed effectiveness trial of crofelemer, marketed as Canalevia-CA1, for chemotherapy-induced diarrhea in dogs.
  • Study showed treated dogs reached normal stool quality by end of treatment, supporting use of drug when started at onset of diarrhea.
  • Owner survey indicated most participants viewed Canalevia-CA1 as effective, with a meaningful share reporting complete resolution of symptoms.
  • Jaguar expects to file full trial analysis to support full FDA approval for this indication.
  • Company also plans to submit results for future scientific publication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604290830ACCESSWRNAPR_____1162317) on April 29, 2026, and is solely responsible for the information contained therein.